Nature Communications (Nov 2016)
Genome-wide RNAi screen reveals ALK1 mediates LDL uptake and transcytosis in endothelial cells
- Jan R. Kraehling,
- John H. Chidlow,
- Chitra Rajagopal,
- Michael G. Sugiyama,
- Joseph W. Fowler,
- Monica Y. Lee,
- Xinbo Zhang,
- Cristina M. Ramírez,
- Eon Joo Park,
- Bo Tao,
- Keyang Chen,
- Leena Kuruvilla,
- Bruno Larriveé,
- Ewa Folta-Stogniew,
- Roxana Ola,
- Noemi Rotllan,
- Wenping Zhou,
- Michael W. Nagle,
- Joachim Herz,
- Kevin Jon Williams,
- Anne Eichmann,
- Warren L. Lee,
- Carlos Fernández-Hernando,
- William C. Sessa
Affiliations
- Jan R. Kraehling
- Department of Pharmacology, Yale University School of Medicine
- John H. Chidlow
- Department of Pharmacology, Yale University School of Medicine
- Chitra Rajagopal
- Department of Pharmacology, Yale University School of Medicine
- Michael G. Sugiyama
- Keenan Research Centre for Biomedical Science, St. Michael's Hospital
- Joseph W. Fowler
- Department of Pharmacology, Yale University School of Medicine
- Monica Y. Lee
- Department of Pharmacology, Yale University School of Medicine
- Xinbo Zhang
- Vascular Biology and Therapeutics Program (VBT), Yale University School of Medicine
- Cristina M. Ramírez
- Vascular Biology and Therapeutics Program (VBT), Yale University School of Medicine
- Eon Joo Park
- Department of Pharmacology, Yale University School of Medicine
- Bo Tao
- Department of Pharmacology, Yale University School of Medicine
- Keyang Chen
- Division of Endocrinology, Department of Medicine, Temple University School of Medicine
- Leena Kuruvilla
- Department of Pharmacology, Yale University School of Medicine
- Bruno Larriveé
- Department of Internal Medicine, Cardiovascular Research Center, Section of Cardiovascular Medicine, Yale University School of Medicine
- Ewa Folta-Stogniew
- W.M. Keck Biotechnology Resource Laboratory, Yale University School of Medicine
- Roxana Ola
- Department of Internal Medicine, Cardiovascular Research Center, Section of Cardiovascular Medicine, Yale University School of Medicine
- Noemi Rotllan
- Vascular Biology and Therapeutics Program (VBT), Yale University School of Medicine
- Wenping Zhou
- Department of Pharmacology, Yale University School of Medicine
- Michael W. Nagle
- Human Genetics & Computational Biomedicine, Pfizer Worldwide Research and Development
- Joachim Herz
- Departments of Molecular Genetics, Neuroscience, Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center
- Kevin Jon Williams
- Division of Endocrinology, Department of Medicine, Temple University School of Medicine
- Anne Eichmann
- Department of Internal Medicine, Cardiovascular Research Center, Section of Cardiovascular Medicine, Yale University School of Medicine
- Warren L. Lee
- Keenan Research Centre for Biomedical Science, St. Michael's Hospital
- Carlos Fernández-Hernando
- Vascular Biology and Therapeutics Program (VBT), Yale University School of Medicine
- William C. Sessa
- Department of Pharmacology, Yale University School of Medicine
- DOI
- https://doi.org/10.1038/ncomms13516
- Journal volume & issue
-
Vol. 7,
no. 1
pp. 1 – 15
Abstract
Atherosclerosis is caused by low-density lipoprotein (LDL) buildup in the vessel wall, a process thought to be mediated by LDL receptor alone. Here, the authors show that the endothelium can uptake LDL via ALK1, a TGFβ signalling receptor, suggesting new therapies for blocking LDL accumulation in the vessel wall.
